Acura Pharmaceuticals, Inc. (ACUR)
-NasdaqCM 2.36 
0.02(0.85%) 4:00PM EDT
| Prev Close: | 2.34 |
|---|
| Open: | 2.25 |
|---|
| Bid: | 2.35 x 500 |
|---|
| Ask: | 2.42 x 6000 |
|---|
| 1y Target Est: | 4.50 |
|---|
| Beta: | 1.66 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.25 - 2.39 |
|---|
| 52wk Range: | 1.06 - 4.50 |
|---|
| Volume: | 267,979 |
|---|
| Avg Vol (3m): | 744,117 |
|---|
| Market Cap: | 109.44M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.24 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Acura Pharmaceuticals Is Grossly Undervalued And Poised For Rapid Growthat Seeking Alpha(Fri, May 17)
- 3 Companies That Put the "Tech" in "Biotech"at Motley Fool(Thu, May 16)
- No Relief in Sight for Pain Investorsat Motley Fool(Sun, May 12)
- Pain Therapeutics, Durect fall on Remoxy reviewAP(Fri, May 10)
- ACURA PHARMACEUTICALS, INC FinancialsEDGAR Online Financials(Wed, May 8)
- Acura Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 3)
- Learn Which Antibody Companies Show Show a Higher Probability of Success; Antibodies Have a Higher Track Record of M&A and More Predictable Toxicology ProfileWall Street Transcript(Fri, May 3)
- Acura Pharmaceuticals Announces First Quarter 2013 Financial ResultsMarketwired(Thu, May 2)
- ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, May 2)
- Q1 2013 Acura Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Thu, May 2)
- Why Did Pain Therapeutics Increase Over 25%?at Seeking Alpha(Thu, May 2)
- The Fool Looks Aheadat Motley Fool(Sat, Apr 27)
- Acura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013Marketwired(Mon, Apr 22)
- Society And The FDA Are Ready For Acura, Are You?at Seeking Alpha(Fri, Apr 19)
- The Hidden Winner of the FDA’s Anti-Generic Decisionat Motley Fool(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | 19.67 |
|---|
| P/S (ttm): | 27,129.37 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.31 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse utilizing its proprietary Aversion and Impede techno...
View More